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Background: Depression is highly prevalent in patients with physical illness and is associated with a
diminished quality of life and poorer medical outcomes. Objective: The authors evaluated whether a
multifaceted intervention conducted by a psychiatric consultation–liaison nurse could reduce the inci-
dence of major depression in rheumatology inpatients and diabetes outpatients with a high level of
case complexity. Method: Of 247 randomized patients, the authors identiﬁed 100 patients with a high
level of case complexity at baseline and without major depression (65 rheumatology and 35 diabetes
patients). Patients were randomized to usual care (N53) or to a nurse-led intervention (N47).
Main outcomes were the incidence of major depression and severity of depressive symptoms during a
1-year follow-up, based on quarterly assessments with standardized psychiatric interviews. Results:
The incidence of major depression was 63% in usual-care patients and 36% in the intervention
group. Effects of intervention on depressive symptoms were observed in outpatients with diabetes but
not in rheumatology inpatients. Conclusion: These preliminary results based on subgroup analysis
suggest that a multifaceted nurse-led intervention may prevent the occurrence of major depression in
complex medically ill patients and reduce depressive symptoms in diabetes outpatients.
(Psychosomatics 2009; 50:227–233)
P
sychiatric comorbidities are highly prevalent in pa-
tients with somatic diseases, and are typically associ-
ated with poor outcomes in terms of quality of life and also
with response to medical treatment.
1–5 Major depression is
among the most frequently observed psychiatric comor-
bidities seen in medical patients, and its presence is spe-
ciﬁcally associated with poor outcomes. Major depression
is highly prevalent in physically ill patients,
6 and it affects
quality of life and course of the somatic illness.
7 However,
treatment of major depression in somatically ill patients
has not been very successful. A series of recent publica-
tions has shown that, in general, antidepressant medication
results in only modest reduction in depressive symptoms.
Turner et al.
8 reported, in a metaanalysis of FDA-reported
trials on antidepressant efﬁcacy, an overall effect size of
0.3, after nonpublished studies were included. Moreover,
when only published trials were included, an effect size of
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have overestimated antidepressant efﬁcacy. Also, Kirsch
et al.
9 reported that the efﬁcacy of antidepressant medica-
tion is actually satisfactory only for severe depressions
(i.e., where the Hamilton Rating Scale for Depression
[Ham-D] score is 29), however, by far, most of the
depressions in the context of a somatic disease do not
fulﬁll this criterion. Large-scale psychotherapeutic studies
on depression in somatic patients, such as the ENRICHD
for postmyocardial infarction,
10 have not been successful
in reducing depressive symptoms, either. Perhaps a differ-
ent approach should therefore be followed; namely, to
prevent depression in somatic patients at high risk.
Strategies to prevent major depression have been de-
scribed mainly in the general population,
11 although some
have been proposed in physically ill patients,
12 mostly
aimed at recurrent depression. Only a few studies have
evaluated the primary prevention of depression in physi-
cally ill patients.
13,14 As recently argued, such strategies
are feasible if an indicator for risk of depression exists.
15
On the basis of our previous work,
16–18 we considered
case complexity, a combination of several illness-re-
lated and psychosocial vulnerability factors, as an indi-
cator for inclusion in a depression prevention program.
We have shown that, with the INTERMED,
19 patients
with a somatic disease with a high risk of psychiatric
comorbidity can be detected. An intervention trial com-
paring an active consultation–liaison psychiatric inter-
vention in INTERMED-detected patients was effective
in reducing length of hospital stay and increasing qual-
ity of life in general-medical patients.
20
The main objective of the present study was to deter-
mine whether a multifaceted intervention by a psychiatric
consultation–liaison nurse, focused on coping with disease
and enhancing compliance with treatment would prevent
the occurrence of depression in medically complex pa-
tients. Elsewhere, we have applied this intervention to a
sample of 247 high-risk patients recruited at a rheumatol-
ogy department and a diabetes outpatient clinic, and
found that it was successful in reducing the prevalence
of major depression, as compared with usual care.
21
Because a substantial proportion of the randomized
sample did not suffer from major depression at baseline,
we had the opportunity to determine whether the inter-
vention was also capable of preventing incident major
depression, and because so few studies have actually
looked at this possibility, we performed this subgroup
analysis in the present study.
METHOD
Data were drawn from a randomized controlled trial that
took place at the University Hospital of Lausanne, Swit-
zerland from 2002 to 2006. The local medical ethics com-
mittee had approved the study protocol, which included a
written informed consent procedure. Details on the study
have been described in a previous report.
21
Patients
The study is a preplanned subgroup analysis of a
randomized, controlled trial. A total of 885 patients were
approached for participation: 1) 229 consecutive patients
with diabetes mellitus (25.9%) consulting the outpatient
clinic of the Division of Endocrinology and Metabolism,
and 2) 656 consecutive patients (74.1%) admitted to the
inpatient unit of the Rheumatology Service of the Univer-
sity Hospital of Lausanne. Patients were excluded if they
did not speak French, suffered from severe cognitive dis-
turbances or terminal illness, were waiting for a planned
placement in an institution, were hospitalized for less
than 3 days, or showed signs of suicide risk. Eligible
patients were included after signing informed consent.
For this subgroup analysis, we excluded patients with a
current major depressive episode at baseline.
Design
Patients were randomized to “usual care” or a nurse-
led intervention arm. Usual care included the possibility
that the treating physician could request a regular psychi-
atric consultation. In the intervention group, a psychiatric
liaison nurse had three different intervention options, of-
fered as a single intervention or combined: 1) supportive
counseling focused on coping with disease and compli-
ance with treatment, facilitated by a psychiatric liaison
nurse; 2) referral to a liaison psychiatrist; and 3) organi-
zation of a multidisciplinary case conference attended by
the treating physicians, nurses, and a liaison psychiatrist.
Assessments
Case complexity was assessed with the INTERMED,
consisting of 20 clinical variables rated by a trained study
nurse according to an instruction manual.
16–18 In the IN-
TERMED, information from a medical history-taking is
classiﬁed into four domains: biological, psychological, so-
cial, and healthcare. In each of the four domains, ﬁve
variables, related to “history,” “current state,” and “prog-
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anchor-points, resulting in a potential score range of 0–60
(higher score indicates increased case complexity). The
ratings are not speciﬁc, but general, and they apply to any
somatic disease. A trained nurse can conduct and reliably
rate the INTERMED interview within 15 minutes. A cut-
off score of 20 was used to indicate a high level of case
complexity and, thus, inclusion in the trial.
19 The
INTERMED has good interrater reliability (: 0.85), test–
retest reliability with a period of 1 year between ratings
(r0.75; : 0.60), and internal consistency (the estimates
of Cronbach  ranging between 0.78 and 0.94 in several
samples of patients with somatic illnesses).
22,23
Outcomes were assessed every 3 months during a
1-year follow-up by a research nurse who was blinded to
the intervention status of the patients. Current major de-
pression was assessed with the depression section of the
validated French version of the Mini-International Neuro-
psychiatric Interview (MINI),
24 a reliable and valid stan-
dardized psychiatric interview to assess the presence of
psychiatric disorders based on DSM–IV criteria. As the
main outcome, we used the cumulative incidence of major
depression during follow-up (e.g., present on at least one
of the follow-up assessments). Severity of depressive
symptoms was assessed with the Center for Epidemiolog-
ical Studies Depression Rating Scale (CES–D), a 20-item
self-report scale to measure depressive symptoms during
the last week, with a score range from 0 to 60.
25 The
CES–D has been proven to be a valid instrument in phys-
ically ill persons.
26 Quality of life was measured at base-
line and at 3 months with the validated French version of
the SF–36.
27 We used only the two summary scores, the
Physical Health Component Score (PCS) and a Mental
Health Component Score (MCS),
28 with a scoring range
between 0 and 100 (100: optimal functioning). Also, we
administered the validated French version of the Visual
Analog Scale (0–100; with a higher score indicating
higher quality of life) of the EuroQoL.
29
Statistical Analyses
Patients in both treatment arms were ﬁrst compared
on baseline variables by chi-square tests for categorical
data and t-tests for continuous data. Effects of intervention
were evaluated by intention-to-treat analyses with respect
to 1) incidence of major depression during follow-up
(MINI); 2) depressive symptoms (CES–D); and 3) quality
of life (EuroQol and SF–36). We evaluated the effects on
incident major depression in two ways. First, we deter-
mined the presence of major depression during a 1-year
follow-up in patients who completed at least two fol-
low-up assessments. Second, we analyzed the effects on
time-related incident major depression by use of a Kaplan-
Meier analysis. To analyze the effects on the CES–D
assessments, we used a mixed-models approach, since
outcomes were assessed repeatedly during follow-up (3, 6,
9, and 12 months post-randomization).
30 We tested a
mixed model consisting of treatment allocation as a factor,
and baseline CES–D and timing of the assessment as
covariates. A preplanned subgroup analysis was conducted
comparing the effects for rheumatology and diabetes pa-
tients separately. For the effects on quality of life at 3
months, we used linear regression, controlling for corre-
sponding baseline functioning.
RESULTS
Of the 885 patients who were assessed for eligibility, 184
were excluded because of the exclusion criteria, and 454
patients did not have a high enough level of case-com-
plexity. Of the remaining 247 patients, 139 were excluded
from the present analyses because they had a major de-
pression at baseline or missing data on baseline depression
rating (N8), resulting in a study sample N of 100 (see
Figure 1). Of these patients, 35 had diabetes (Type 1:
N8; Type 2: N22; other: N5), and 65 were recruited
from the rheumatology ward (inﬂammatory-based disor-
der: N15; degenerative or pain: N41; age-related:
N1; other [mainly ﬁbromyalgia]): N8).
Patients in the Usual-Care and Intervention arm did
not signiﬁcantly differ with regard to sociodemographic
variables and baseline measurements except for a nonsig-
niﬁcant difference in education level and severity of de-
pressive symptoms (Table 1). In subsequent analyses
(mixed-models analyses), we therefore controlled for
baseline severity of depression symptoms. In the Interven-
tion arm, most patients (N41/47; 87.2%) received at
least one intervention conducted by the psychiatric liaison
nurse (median: 8 sessions; interquartile range [IQR]: 3.5–
11). The interventions, performed as single interventions
or combined, consisted of “facilitating emotional expres-
sion” (70.7%), “giving practical advice” (65.9%), “pro-
moting life-narrative” (43.9%), and “psycho-education”
(48.8%). A minority of patients received psychiatric con-
sultations (N7; 17.0%), psychiatric advice to the treating
physician (N2; 4.8%), interdisciplinary case-confer-
ences (N3; 7.3%), or no additional intervention (because
de Jonge et al.
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motivation; N6; 12.8%).
The Intervention condition was associated with a
lower incidence of major depression (36.4% versus
63.2%; p0.02; Table 2). In logistic-regression analysis,
the intervention was associated with a decreased risk of
major depression (odds ratio [OR]: 0.33; 95% conﬁdence
interval [CI]: 0.13–0.88; p0.02), which largely remained
although the statistical signiﬁcance disappeared (OR: 0.39;
95% CI: 0.14–1.09; p0.14). When comparing the treat-
ment arms on time-related incidence of major depression
by use of a Kaplan-Meier survival analysis, we found a
(tendency to) a prolonged event-free survival in the Inter-
vention arm (log-rank: 3.1; p0.08; estimated mean time
to event, Care-As-Usual: 7.9 months (95% CI: 6.7–9.0)
and Intervention: 9.2 (95% CI: 8.0–10.4). Using Cox regres-
sion analysis, we found a nonsigniﬁcant decreased risk of
major depression (OR: 0.60; 95% CI: 0.31–1.16; p0.13),
which was somewhat reduced after controlling for baseline
CES–D (OR: 0.69; 95% CI: 0.35–1.36; p0.29).
Mixed-models analysis of the differences on CES–D
yielded a 1.6-point decreased level of depressive symp-
toms in the Intervention arm, after controlling for baseline
CES–D and timing of assessment (95% CI: –1.2 to 4.4;
p0.26). Effect sizes for diabetes and rheumatology pa-
tients separately were 6.2 (95% CI: 1.7–10.6; p0.007)
and 1.3 points (–2.2 to 4.9; p0.46), respectively (Figure
2). Controlling for baseline functioning, Intervention was
associated with OR: 2.9 (95% CI: –1.2 to 6.9; 0.14;
p0.16), higher scores on the PCS: (OR: 2.1; 95% CI:
–3.9 to 8.1; 0.09; p0.48), higher scores on the MCS:
OR: 8.3; 95% CI: 0.1–16.5; 0.22; p0.047), and a
higher score on the EuroQol VAS.
Rheumatology patients reported signiﬁcantly more
pain, assessed with the EuroQol–5 at baseline (no pain:
0.0%; moderate pain: 53.8%; severe pain: 46.2%) than di-
FIGURE 1. Patient Flow Chart
Exclusion criteria (N=184)
Language problem (N=43)
Cognitive problem (N=27) 
Terminal illness (N=9) 
Placement (N=12) 
Hospitalization<3 days (N=28) 
Suicidal risk (N=4) 
Logistic problem (N=6) 
Refusal (N=55)
Assessed for eligibility (N=885)
INTERMED<21 (N=454)
Randomized (N=247)
RA (N=162); DM (N=85)
Major depression (N=139)
Data missing (N=8)
Used in present study (N=100)
Intervention (N=47)
RA (N=30); DM (N=17)
Usual care (N=53)
RA (N=35); DM (N=18)
Analyzed (N=47) 
≥2 MINI interviews 
available N=33 
CES-D 3 months N=32
CES-D 6 months N=32
CES-D 9 months N=27
CES-D 12 months N=29
Analyzed (N=53) 
≥2 MINI interviews 
available N=38 
CES-D 3 months N=35
CES-D 6 months N=30
CES-D 9 months N=32
CES-D 12 months N=38
RA: rheumatoid arthritis; DM: diabetes mellitus.
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vere pain: 17.1%; 
217.0; p0.001), and more depressive
symptoms (mean CES–D noted in rheumatology patients:
21.3 (standard deviation [SD]: 8.7); diabetes patients: 17.4
(SD: 10.1). The intervention was effective in preventing ma-
jor depression in subjects with no or moderate pain (inter-
vention: 30.4%; Care-As-Usual: 60.0%; 
24.2; p0.04)
but not in patients with severe pain (Intervention: 50.0%
versus 69.2%; 
20.9; p0.35). The intervention was effec-
tive in preventing major depression in patients with a baseline
CES–D20 (Intervention: 50.0% versus 85.7%; 
25.3;
p0.02) but not in patients with a baseline CES–D 20
(Intervention: 26.3% versus 35.3%; 
20.3; p0.56).
DISCUSSION
The aim of this study was to evaluate whether a preventive
intervention by a psychiatric nurse targeted at complex
medically ill patients could reduce the incidence of major
depression and depressive symptoms. Results showed that
patients in the intervention arm of the study suffered less
frequently from incident major depression during the
1-year follow-up. Moreover, reductions in depressive
symptoms were observed in diabetes outpatients, and, on
one of the three quality-of-life indicators, a positive effect
of intervention was found.
With respect to depressive symptoms, we found that
intervention effects were restricted to outpatients with di-
abetes. We explored two options to explain this ﬁnding.
First, the differential effectiveness may have been due to
the possibility that rheumatology patients had more de-
pressive symptoms at baseline and that our intervention,
dominated by supportive counseling by a psychiatric
nurse, was effective only for patients with relatively mild
depressive symptoms. This explanation was not supported
TABLE 1. Comparison of the Two Treatment Arms on
Baseline Variables
Intervention
(N47)
Usual Care
(N53) p
Mean age, years (SD) 52.4 (13.9) 53.4 (16.7) 0.76
Female sex 61.7% 54.7% 0.48
Level of education 0.09
Low 34.0% 55.8%
Middle 34.0% 25.0%
High 31.9% 19.2%
Professional level 0.16
Low 31.9% 45.3%
Middle 53.2% 35.8%
High 14.9% 18.9%
Rheumatology inpatients 36.2% 34.0% 0.49
Diabetes outpatients 63.8% 66.0%
Depressive symptoms
(CES–D; mean, SD)
18.3 (8.8) 21.5 (9.7) 0.09
SD: standard deviation.
TABLE 2. Comparison of Intervention Arm and Usual-Care
Arm on Outcomes at 3, 6, 9, and 12 Months Post-
Randomization
Intervention Usual Care p
Major depression 36.4% 63.2% 0.02
Depressive symptoms,
mean (SD)
3 months 20.0 (11.8) 23.8 (11.3) 0.18
6 months 21.5 (12.8) 23.6 (12.8) 0.53
9 months 18.4 (10.5) 22.6 (13.9) 0.20
12 months 19.4 (12.1) 23.8 (14.9) 0.20
SD: standard deviation.
FIGURE 2. Course of Depressive Symptoms (CES–D) for
Intervention Versus Usual-Care Patients in the
Rheumatology and Diabetes Subsamples
14
Baseline 12 Months 9 Months 6 Months 3 Months
C
E
S
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D
24
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26
28
14
Baseline 12 Months 9 Months 6 Months 3 Months
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D
24
22
20
18
16
26
28
[A] Rheumatolo gy Subsample
[B] Diabetes Subsample
Intervention
Care as Usual
Intervention
Care as Usual
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patients with higher levels of depressive symptoms at
baseline. A second explanation seems more plausible;
namely, that rheumatology inpatients had more pain com-
plaints, which, in our present study, may have reduced the
effects of the intervention. In support of this hypothesis,
we found that rheumatology patients had more pain com-
plaints and that our intervention was speciﬁcally effective
in patients without severe pain complaints at baseline.
The multifaceted psychiatric interventions have been
mainly facilitated and organized by psychiatric liaison
nurses. Only patients who needed further assessment or
psychopharmacological treatment were referred to a liai-
son psychiatrist, or advice concerning psychiatric manage-
ment was given to the treating physician, which happened
in only a minority of patients. Interdisciplinary case con-
ferences were only rarely organized. This approach to
preventing depression in complex medically ill patients
therefore seems feasible and effective, speciﬁcally in dia-
betes patients and/or patients without severe initial pain
complaints.
The level of depressive symptoms at baseline in our
sample of patients was around 20 on the CES–D scale.
This means that most patients might be considered to have
subclinical depression at the start of the study. Our inter-
vention prevented the onset of depression in this vulnera-
ble group by means of relatively simple interventions con-
ducted by a nurse. Recently, a metaanalysis was done on
the effects of psychological treatments of subthreshold
depression,
31 which reported an OR of 0.70 (95% CI:
0.47–1.03) for preventing the onset of major depression.
Of these studies, only one
32 was conducted in medically ill
patients, and the intervention, interpersonal counseling,
was effective in reducing depressive symptoms. Most of
the other interventions described in this metaanalysis were
rather structured, cognitive–behavior therapy-based inter-
ventions. In contrast, our intervention was less structured,
multifaceted, and, in general, more focused on coping,
well integrated into clinical care, and apparently more
effective (OR: 0.33; 95% CI: 0.13–0.88). Perhaps this
indicates that depression prevention strategies for sub-
threshold depression are effective speciﬁcally when they
are ﬂexible. Another possibility is that our ﬁndings stress
the importance of indication criteria for intervention,
which was supported by the substantial differences in ef-
fectiveness among our two patient subsamples.
Some limitations need to be considered in interpreting
our ﬁndings. Because our ﬁndings were based on a sub-
group analysis of a randomized, controlled trial, they need
to be considered as preliminary, and replication is war-
ranted. Moreover, we did not document the exact care
given in the usual-care group and did not have information
on antidepressant use at baseline. However, it is well
known that only a minority of physically ill patients with
psychiatric problems actually receive psychiatric care,
which may even be worse with respect to patients suffer-
ing from subclinical problems, as in our subsample. An-
other limitation is that, at baseline, signiﬁcant differences
have emerged on the CES–D scale between the two treat-
ment conditions. However, in order to prevent bias due to
this difference, in multivariate analyses, we subsequently
controlled for baseline CES–D, which did not substantially
alter our ﬁndings.
In conclusion, we found that in high-risk patients with
somatic disease and a high level of case complexity, a
nurse intervention was effective in reducing the incidence
of major depression. Future efforts should further explore
targeting relevant patient groups for which these interven-
tions work, and conﬁrmation in larger samples needs to be
sought.
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